| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PSMD10 |
| Uniprot No | O75832 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-226aa |
| 氨基酸序列 | MEGCVSNLMVCNLAYSGKLEELKESILADKSLATRTDQDSRTALHWACSAGHTEIVEFLLQLGVPVNDKDDAGWSPLHIAASAGRDEIVKALLGKGAQVNAVNQNGCTPLHYAASKNRHEIAVMLLEGGANPDAKDHYEATAMHRAAAKGNLKMIHILLYYKASTNIQDTEGNTPLHLACDEERVEEAKLLVSQGASIYIENKEEKTPLQVAKGGLGLILKRMVEG |
| 预测分子量 | 40.4kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PSMD10重组蛋白的3篇参考文献及其摘要概括：
---
1. **文献名称**: *Gankyrin: A novel oncogenic protein in human hepatocarcinogenesis*
**作者**: Yokota T, et al.
**摘要**: 该研究首次报道了PSMD10(又称gankyrin)作为肝癌中过度表达的癌基因蛋白，通过重组蛋白技术证实其与CDK4和MDM2的相互作用，揭示了其通过泛素-蛋白酶体通路调控细胞周期和p53蛋白稳定性的分子机制。
2. **文献名称**: *PSMD10 promotes hepatocellular carcinoma progression through activating the mTORC1 signaling pathway*
**作者**: Chen L, et al.
**摘要**: 研究利用重组PSMD10蛋白进行功能实验，发现其通过激活mTORC1信号通路促进肝癌细胞增殖和侵袭，并证明PSMD10高表达与肝癌患者预后不良相关，为靶向治疗提供了潜在靶点。
3. **文献名称**: *Structural basis for the recognition of PSMD10 by the 26S proteasome*
**作者**: Liu Z, et al.
**摘要**: 通过重组PSMD10蛋白的晶体结构解析，揭示了其与26S蛋白酶体亚基的相互作用界面，阐明了PSMD10在蛋白酶体组装和底物识别中的关键作用，为设计小分子抑制剂奠定结构基础。
---
以上文献涵盖了PSMD10在癌症机制、信号通路及结构生物学中的研究，均为重组蛋白技术支撑的关键成果。如需更多文献或具体细节，可进一步补充关键词或研究方向。
**Background of PSMD10 Recombinant Protein**
PSMD10 (Proteasome 26S Subunit, Non-ATPase 10), also known as gankyrin or p28. is a regulatory component of the 26S proteasome, a multi-subunit complex responsible for ubiquitin-dependent protein degradation. This ATP-independent chaperone plays a critical role in maintaining cellular protein homeostasis by facilitating the assembly and stability of the proteasome. Structurally, PSMD10 contains six ankyrin repeats that mediate protein-protein interactions, enabling its binding to key partners like the 19S regulatory particle and the oncoprotein MDM2.
PSMD10 is implicated in diverse cellular processes, including cell cycle regulation, apoptosis, and oncogenesis. Overexpression of PSMD10 is frequently observed in cancers such as hepatocellular carcinoma (HCC), where it promotes tumor progression by stabilizing MDM2 to degrade p53. thereby inhibiting apoptosis. Conversely, reduced PSMD10 levels correlate with disrupted proteasome function, potentially contributing to neurodegenerative disorders.
Recombinant PSMD10 protein is produced using expression systems like *E. coli* or mammalian cells, enabling studies on its structural and functional roles. This purified protein serves as a vital tool for *in vitro* assays, including binding studies, enzymatic activity assays, and drug discovery targeting proteasome dysregulation. Its recombinant form also aids in elucidating molecular mechanisms underlying cancer biology and neurodegenerative diseases, offering insights for therapeutic strategies.
Research on PSMD10 continues to expand, emphasizing its dual role as a proteasome assembly factor and an oncogenic driver, highlighting its potential as a diagnostic marker or therapeutic target in precision medicine.
×
